Ngā hua rapu - Paul Aisen

Whakamahine hua
  1. 1
    Alzheimer's disease therapeutic research: the path forward

    Alzheimer's disease therapeutic research: the path forward mā Paul Aisen

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Editorial
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Advances in Alzheimer’s Disease Drug Development

    Advances in Alzheimer’s Disease Drug Development mā Michael S. Rafii, Paul Aisen

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Recent developments in Alzheimer's disease therapeutics

    Recent developments in Alzheimer's disease therapeutics mā Michael S. Rafii, Paul Aisen

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

    Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease mā Paul Aisen, Bruno Vellas, Harald Hampel

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

    Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease mā Paul Aisen, Joanne Cummings, L. S. Schneider

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Testing the Right Target and Right Drug at the Right Stage

    Testing the Right Target and Right Drug at the Right Stage mā Reisa A. Sperling, Clifford R. Jack, Paul Aisen

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans

    Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans mā Paul Aisen, Ronald C. Petersen, Michael Donohue, Michael W. Weiner

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review

    Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review mā Nicola Coley, Caroline Giulioli, Paul Aisen, Bruno Vellas, Sandrine Andrieu

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice

    A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice mā Takako Niikura, Elkhansa Sidahmed, Chiho Hirata‐Fukae, Paul Aisen, Yasuji Matsuoka

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease

    Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease mā Robert A. Rissman, John Q. Trojanowski, Leslie M. Shaw, Paul Aisen

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Effect of study partner on the conduct of Alzheimer disease clinical trials

    Effect of study partner on the conduct of Alzheimer disease clinical trials mā Joshua D. Grill, Rema Raman, Karin Ernström, Paul Aisen, Jason Karlawish

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding

    The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding mā Laurel Beckett, Michael Donohue, Cathy Wang, Paul Aisen, Danielle Harvey, Naomi Saito

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention

    Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention mā Philip S. Insel, Elizabeth C. Mormino, Paul Aisen, Wesley K. Thompson, Michael Donohue

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Predicting the course of Alzheimer’s progression

    Predicting the course of Alzheimer’s progression mā Samuel Iddi, Dan Li, Paul Aisen, Michael S. Rafii, Wesley K. Thompson, Michael Donohue

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Aducanumab: Appropriate Use Recommendations

    Aducanumab: Appropriate Use Recommendations mā Joanne Cummings, Paul Aisen, Liana G. Apostolova, Alireza Atri, Stephen Salloway, Michael W. Weiner

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

    PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease mā Marwan N. Sabbagh, Albert Agro, J. Simon Bell, Paul Aisen, Edward E. Schweizer, Douglas Galasko

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

    Aducanumab produced a clinically meaningful benefit in association with amyloid lowering mā Jeffrey L. Cummings, Paul Aisen, Cynthia A. Lemere, Alireza Atri, Marwan N. Sabbagh, Stephen Salloway

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Health‐Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment

    Health‐Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment mā Carolyn W. Zhu, Mary Sano, Steven H. Ferris, Peter J. Whitehouse, Marian B. Patterson, Paul Aisen

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

    Effect of TTP488 in patients with mild to moderate Alzheimer’s disease mā Aaron H. Burstein, Imogene Grimes, Douglas Galasko, Paul Aisen, Marwan N. Sabbagh, Adnan M.M. Mjalli

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

    Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease mā Charbel Moussa, Michaeline Hebron, Xu Huang, Jaeil Ahn, Robert A. Rissman, Paul Aisen, Raymond Scott Turner

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: